CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Total revenues	$ 967	$ 174
Operating expenses:
Research and development	26,798	17,056
General and administrative	6,640	6,911
Gain on fair value remeasurement of contingent consideration	0	(536)
Total operating expenses	33,438	23,431
Operating loss	(32,471)	(23,257)
Investment and other income, net	3,110	207
Net loss	$ (29,361)	$ (23,050)
Basic and diluted net loss per common share	$ (0.62)	$ (0.49)
Basic and diluted net loss per common share	$ (0.62)	$ (0.49)
Shares used in calculating basic and diluted net loss per share	47,214	46,739
Shares used in calculating basic and diluted net loss per share	47,214	46,739
Comprehensive loss:
Net loss	$ (29,361)	$ (23,050)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	863	(1,782)
Comprehensive loss	(28,498)	(24,832)
Product development and licensing agreements
Revenues:
Total revenues		30
Contracts and grants
Revenues:
Total revenues	$ 967	$ 144